Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EPRX
DateTimeSourceHeadlineSymbolCompany
20/11/202413:57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
20/11/202412:00PR Newswire (US)Eupraxia's DiffuSphereâ„¢ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
20/11/202412:00PR Newswire (Canada)Eupraxia's DiffuSphereâ„¢ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
14/11/202422:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
14/11/202422:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingNASDAQ:EPRXEupraxia Pharmaceuticals Inc
14/11/202422:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingNASDAQ:EPRXEupraxia Pharmaceuticals Inc
13/11/202422:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
13/11/202422:00PR Newswire (Canada)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
13/11/202422:00PR Newswire (US)Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
12/11/202422:56PR Newswire (US)Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
12/11/202422:56PR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
08/11/202416:49Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/11/202422:17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/11/202422:00PR Newswire (US)Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/11/202422:00PR Newswire (Canada)Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial ResultsNASDAQ:EPRXEupraxia Pharmaceuticals Inc
07/11/202421:10Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:EPRXEupraxia Pharmaceuticals Inc
31/10/202423:36PR Newswire (US)Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionNASDAQ:EPRXEupraxia Pharmaceuticals Inc
31/10/202423:36PR Newswire (Canada)Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionNASDAQ:EPRXEupraxia Pharmaceuticals Inc
28/10/202411:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
28/10/202411:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
28/10/202411:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
15/10/202412:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
15/10/202411:00PR Newswire (Canada)Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee OsteoarthritisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
15/10/202411:00PR Newswire (US)Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee OsteoarthritisNASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/10/202411:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/10/202411:00PR Newswire (Canada)Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
10/10/202411:00PR Newswire (US)Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024NASDAQ:EPRXEupraxia Pharmaceuticals Inc
02/10/202421:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:EPRXEupraxia Pharmaceuticals Inc
02/10/202421:01PR Newswire (Canada)Eupraxia Pharmaceuticals Strengthens Senior Management TeamNASDAQ:EPRXEupraxia Pharmaceuticals Inc
02/10/202421:01PR Newswire (US)Eupraxia Pharmaceuticals Strengthens Senior Management TeamNASDAQ:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EPRX

Your Recent History